Thymosin Beta 4: Protein, Science & Trials

Medically reviewed by Amber Patel, MD. Nouri content is reviewed by licensed clinicians and updated as guidance changes.

What is thymosin beta 4 and what does it do in the body?

Thymosin beta 4 is a small, naturally occurring protein — a chain of 43 amino acids — that your body already makes. It is the most abundant member of the beta-thymosin family, accounting for roughly 70-80% of cellular beta-thymosin, and it turns up in nearly every cell type except red blood cells. So this isn't an exotic foreign compound; it's an endogenous molecule that scientists have been characterizing for decades.

Its clearest, most established job is actin sequestration. Actin assembles into a cell's internal scaffolding — the cytoskeleton that lets cells hold shape, divide, and crawl. Thymosin beta 4 binds monomeric G-actin and holds a reserve pool of it, so the cell can rapidly build or dismantle its skeleton when it needs to move. Because cell migration underlies wound repair, a 2021 review in Frontiers in Endocrinology catalogs the downstream effects research has attributed to the protein: VEGF-driven angiogenesis, NF-κB-linked anti-inflammatory signaling, and keratinocyte migration in wound-healing models (Xing et al., Frontiers in Endocrinology, 2021).

The protein also has distinct functional regions — an anti-inflammatory segment near amino acids 1-4, an anti-apoptotic region around 1-15, and an angiogenic, hair-follicle-active fragment at residues 17-23. That last fragment matters for the next section, because it is exactly the piece the injectable sold as "TB-500" is built to imitate.

Where does the mechanism research come from?

The foundational mechanism work is a 2004 Nature paper showing that thymosin beta 4 activated integrin-linked kinase (ILK) and the Akt survival pathway, and promoted the migration and survival of cardiac and endothelial cells in the mouse heart (Bock-Marquette et al., Nature, 2004). A follow-up reported that the protein was cardioprotective after myocardial infarction in animal models, reducing cell death and improving cardiac function (Srivastava et al., Annals of the NY Academy of Sciences, 2007).

Read those carefully: they describe a mechanism in cells and animals. They're the reason people got interested in thymosin beta 4 as a repair molecule — but "promotes cell migration in a mouse heart" is a mechanistic finding, not a demonstrated human therapy. That gap between mechanism and proven human benefit is the theme of this whole article.

What is the difference between thymosin beta 4 and TB-500?

This is the single most important distinction on this page, and it's where a lot of online marketing gets muddy. Thymosin beta 4 is the full 43-amino-acid protein. TB-500 is not that protein. TB-500 is a synthetic, N-acetylated fragment corresponding to residues 17-23 (the sequence Ac-LKKTETQ), which is the actin-binding domain of the parent molecule (Wikipedia: TB-500).

	Thymosin beta 4 (full protein)	TB-500 (fragment)
What it is	Naturally occurring 43-amino-acid protein	Synthetic ~7-residue fragment (Ac-LKKTETQ, aa 17-23)
Human trials	Yes — registered Phase 1/2/3 (topical/ophthalmic/post-MI)	None completed and published for injury/athletic use
How studied	Eye drops, dermal, cardiac safety — physician-supervised	Self-injected, "research use only," online-sourced
FDA status	Investigational; not approved for any indication	Not approved; not on the 503A Bulks List
WADA	Prohibited (parent molecule and derivatives)	Prohibited at all times

So when someone points to a thymosin beta 4 eye-drop trial as "proof TB-500 works," they are conflating two different things: a physician-administered topical drug based on the whole protein, and a self-injected fragment with no comparable human evidence. For a fuller breakdown of the injectable, see our pillar on what TB-500 is and how it's used, the benefit-by-benefit review in TB-500 benefits and the evidence behind them, and the safety-first look at reported TB-500 dosage and its risks.

What do the real human trials of thymosin beta 4 actually show?

Here's the part that makes thymosin beta 4 genuinely different from most gray-market peptides: the full protein really has been through registered human trials. But those trials are in narrow medical indications, and the results are mixed rather than uniformly positive.

Dermal wound healing. Research investigated topical thymosin beta 4 (as RGN-137) in human Phase 2 trials for pressure ulcers, venous stasis ulcers, and epidermolysis bullosa wounds, where it was reported safe and well tolerated alongside broad preclinical wound-healing data (Kleinman & Sosne, Vitamins and Hormones, 2016). A registered Phase 2 dermal wound-healing trial of the molecule is on file with the sponsor RegeneRx (ClinicalTrials.gov NCT00311766).

Corneal and ocular healing. This is the strongest human data — and it's an eye drop, not an injection. In a Phase 2 randomized trial for severe dry eye, the RGN-259 (thymosin beta 4) ophthalmic solution reduced ocular discomfort by about 35.1% and corneal staining by about 59.1% versus vehicle (Sosne et al., Cornea, 2015). A subsequent Phase 3 trial in neurotrophic keratopathy reported complete healing in 6 of 10 patients on RGN-259 versus 1 of 8 on placebo, though that difference did not reach statistical significance (p=0.0656) (Sosne et al., International Journal of Molecular Sciences, 2023).

Did a thymosin beta 4 trial ever fail?

Yes — and this matters, because it's the honest counterweight to the healing headlines. The confirmatory EU Phase 3 trial of RGN-259 for neurotrophic keratitis, known as SEER-3, missed its primary endpoint, a result the developer attributed largely to a strong placebo response (Ophthalmology Times, 2024; corroborated by Korea Biomedical Review, 2024).

Sit with what that means. Even the legitimate, well-funded, physician-supervised development of thymosin beta 4 — with pharmaceutical manufacturing, dosing science, and regulatory oversight behind it — has produced mixed human results, including a failed pivotal trial in a specific eye condition. None of that careful work says anything about whether a self-injected fragment from an online vendor helps a torn tendon. A house scoping review of the tissue-healing literature reaches the blunt conclusion that the evidence is largely preclinical with limited human data, and that human evidence for injury or athletic use is essentially absent (Applied Sciences, 2026).

Is thymosin beta 4 the same as thymosin alpha-1?

No — this is a common mix-up worth clearing. Thymosin alpha-1 is a separate, 28-amino-acid immune-modulating peptide; thymosin beta 4 is the 43-amino-acid actin-sequestering protein described here. They share the "thymosin" label because both were first isolated from thymus tissue, not because they do the same thing. If a source treats them as interchangeable, that's a signal to be skeptical of it.

Is thymosin beta 4 FDA-approved or legal?

No thymosin beta 4 product is FDA-approved for any therapeutic use, and neither the protein nor the TB-500 fragment is on the 503A Bulks List — meaning there is no legal pathway to compound or sell it for people today. Products marketed as "TB-500" are sold "for research use only," a label that means they are explicitly not manufactured or quality-controlled for human use.

The regulatory picture is also active. The FDA's Pharmacy Compounding Advisory Committee reviewed this class of peptides on July 23-24, 2026 (docket FDA-2025-N-6895), and FDA staff proposed not to add these substances to the Bulks List, citing that they are poorly characterized, have little human efficacy evidence, and carry unassessed immunogenicity risk (Federal Register, FDA-2025-N-6895). Important nuance: the PCAC is advisory and non-binding, and a final rule would require formal notice-and-comment rulemaking. So this is a staff proposal, not a ban or a final ruling.

On the sport side, thymosin beta 4 and its derivatives — explicitly including TB-500 — are on the WADA Prohibited List under Section S2, prohibited at all times, in and out of competition (BSCG: TB-500 status in sport and military). Athletes have received multi-year bans for using it.

Where Nouri fits, and why sourcing matters

Nouri does not sell thymosin beta 4, TB-500, or any research peptide, and — as the regulatory section above lays out — there is no legal, quality-controlled way to buy them for human use right now. We're writing about this molecule because people are searching for straight answers, and the gray market is where they usually land instead.

That gray market is the real hazard. Independent testing of injectable peptides sold online without a prescription found purity as low as 7.7-14.37% against "99%" label claims, endotoxin contamination in 100% of samples, and most products failing basic visual-quality criteria (JMIR, 2024). A "99% pure" certificate tests identity only — whether the vial contains the right sequence — not whether it is sterile or endotoxin-free. You can hit the identity spec and still be injecting a contaminated product.

If and when a licensed, tested peptide option ever becomes available through a legitimate clinical channel, we want the people who trust Nouri to hear about it first — from a compliance-led source, not a research-chemical vendor. Join the Nouri peptide waitlist to be first to know if and when licensed peptide options become available: joinnouri.com/peptides.

Separately, if your actual goal is metabolic health and weight management, that's a space with FDA-approved medications and real physician oversight today — you can explore Nouri's weight-loss program to see if you qualify.

Frequently asked questions

What is thymosin beta 4 and what does it do? It's a naturally occurring 43-amino-acid protein found in nearly all human cells except red blood cells. Its main known function is sequestering G-actin — holding a reserve pool of the protein that builds a cell's cytoskeleton — which research has linked to cell migration, angiogenesis, and wound-healing signaling in lab and animal models.

Where is thymosin beta 4 found in the body? Almost everywhere. It's the most abundant beta-thymosin, making up roughly 70-80% of cellular beta-thymosin, and appears in nearly every cell type except red blood cells.

What is the difference between thymosin beta 4 and TB-500? Thymosin beta 4 is the full 43-amino-acid protein; TB-500 is a synthetic fragment of just residues 17-23 (Ac-LKKTETQ). The full protein has registered human trials as a topical or eye-drop drug; the injectable TB-500 fragment has no completed published human trial for injury or athletic use.

Is thymosin beta 4 approved as a drug (RGN-259)? No. RGN-259 and related formulations are investigational and have been tested in humans, but none is FDA-approved. Results are mixed — Phase 2 dry-eye and Phase 3 neurotrophic-keratopathy signals, but the confirmatory Phase 3 SEER-3 eye-drop trial missed its primary endpoint.

Does thymosin beta 4 help wound or corneal healing? Research has investigated it for both, with Phase 2 signals in certain skin ulcers and in severe dry eye as an eye drop. These are narrow, physician-supervised medical uses of the full protein — not established therapies, and not evidence for a self-injected fragment.

Is thymosin beta 4 the same as thymosin alpha-1? No. Thymosin alpha-1 is a distinct 28-amino-acid immune-modulating peptide with different structure and biology. They share the "thymosin" name only because both were originally isolated from thymus tissue.

Sources & data

Bock-Marquette et al., "Thymosin β4 activates ILK and promotes cardiac cell migration, survival and cardiac repair," Nature, 2004 (Tier 1).
Srivastava et al., "Thymosin beta4 is cardioprotective after myocardial infarction," Annals of the NY Academy of Sciences, 2007 (Tier 1).
Xing et al., "Progress on the Function and Application of Thymosin β4," Frontiers in Endocrinology, 2021 (Tier 1).
Kleinman & Sosne, "Thymosin β4 Promotes Dermal Healing," Vitamins and Hormones, 2016 (Tier 1).
Sosne et al., "0.1% RGN-259 (Thymosin β4) Ophthalmic Solution … Neurotrophic Keratopathy … Phase III Clinical Trial," International Journal of Molecular Sciences, 2023 (Tier 1).
Sosne et al., "Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial," Cornea, 2015 (Tier 1).
RegeneRx Phase 2 dermal wound-healing trial, ClinicalTrials.gov NCT00311766 (Tier 2, trial registry).
"Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review," Applied Sciences, 2026 (Tier 1).
"HLB Therapeutics misses primary endpoint in phase 3 SEER-3 trial of RGN-259," Ophthalmology Times, 2024 (Tier 2, trade news).
"HLB's eye drop rival to Dompé's Oxervate misses mark in EU phase 3," Korea Biomedical Review, 2024 (Tier 2, news).
"TB-500," Wikipedia (Tier 2, sourced encyclopedia).
"Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription," JMIR, 2024 (Tier 1).
Federal Register — PCAC Notice of Meeting, Docket FDA-2025-N-6895 (Tier 1, primary regulatory).
BSCG — "TB-500: Status, Risks, and Bans in Sport and Military" (Tier 2, anti-doping lab).

This article is educational and is not medical advice. Thymosin beta 4 and TB-500 are not FDA-approved, are not on the 503A Bulks List, and are prohibited under WADA; there is no legal, quality-controlled way to buy them for human use today.

Want to know if a licensed, tested peptide option ever becomes available? Join the Nouri peptide waitlist — a compliance-first source, not a research-chemical vendor.